

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Hodge et al.

**Application No.** 10/535,523

**Filed:** March 24, 2006

**Confirmation No.** 8826

**For:** CELL LINES AND HOST NUCLEIC ACID  
SEQUENCES RELATED TO INFECTIOUS  
DISEASE

**FILED VIA EFS ON MAY 11, 2007**

**Examiner:** Agnieszka Boesen

**Art Unit:** 1648

**Attorney Reference No.** 6395-66741-06

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

SUBMITTED VIA ELECTRONIC FILING SYSTEM  
UNITED STATES PATENT AND TRADEMARK OFFICE

Listed on the accompanying form PTO-1449 and enclosed herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By   
Sheree Lynn Rybak, Ph.D.  
Registration No. 47,913

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Attorney Docket Number	6395-66741-06
	Application Number	10/535,523
	Filing Date	March 24, 2006
	First Named Inventor	Hodge
	Art Unit	1648
	Examiner Name	Agnieszka Boesen

### U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		5,616,472	04/01/1997	Choi et al.

### FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO2005/092924 A2	10/06/2005	The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Argaet et al., "Dominant Selection of an Invariant T Cell Antigen Receptor in Response to Persistent Infection by Epstein-Barr Virus," <i>J. Exp. Med.</i> 180:2335-2340, 1994.
		Gavrilovskaya et al., " $\beta_3$ Integrins Mediate the Cellular Entry of Hantaviruses that Cause Respiratory Failure," <i>Proc. Natl. Acad. Sci. USA</i> 95:7074-7079, 1998.
		Groh et al., "Costimulation of CD8 $\alpha\beta$ T Cells by NKG2D via Engagement by MIC Induced on Virus-Infected Cells," <i>Nature Immunol.</i> 2:255-260, 2001.

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	